Activation states of blood eosinophils in asthma

Clinical and Experimental Allergy

Volumn 44, Issue 4, 2014, Pages 482-498

  Johansson, M W ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA1 INTEGRIN; CD11B ANTIGEN; CD18 ANTIGEN; CD4 ANTIGEN; CD45RO ANTIGEN; CD48 ANTIGEN; CD63 ANTIGEN; CD69 ANTIGEN; CD81 ANTIGEN; CD9 ANTIGEN; COMPLEMENT COMPONENT C3B RECEPTOR; CYTOKINE RECEPTOR; FC RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERMES ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 13; INTERLEUKIN 25; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; L SELECTIN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MEMBRANE PROTEIN; MICROSOMAL AMINOPEPTIDASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY KIM 127; MONOCLONAL ANTIBODY N29; P SELECTIN GLYCOPROTEIN LIGAND 1; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; MEMBRANE ANTIGEN;

ASTHMA; CELL ACTIVATION; CLINICAL FEATURE; DISEASE ASSOCIATION; DOWN REGULATION; EOSINOPHIL; EOSINOPHILIA; HUMAN; IN VITRO STUDY; LUNG FUNCTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; REVIEW; UPREGULATION; ANIMAL; IMMUNOLOGY; METABOLISM;

ANIMALS; ANTIGENS, SURFACE; ASTHMA; BIOLOGICAL MARKERS; EOSINOPHILS; HUMANS;

EID: 84897889300     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12292     Document Type: Review

References (214)

1. Thomas A, Busse WW. The evolving role of eosinophils in asthma. In: Lee JJ, Rosenberg HF, eds. Eosinophils in health and disease. Amsterdam: Elsevier, 2013: 448-62.
2. Scott KA, Wardlaw AJ. Eosinophilic airway disorders. Semin Respir Crit Care Med 2006; 27:128-33.
3. Blanchard C, Rothenberg ME. Biology of the eosinophil. Adv Immunol 2009; 101: 81-121.
4. Kita H. Eosinophils: multifaceted biological properties and roles in health and disease. Immunol Rev 2011; 242:161-77.
5. Rosenberg HF, Dyer KD, Foster PS. Eosinophils: changing perspectives in health and disease. Nat Rev Immunol 2013; 13:9-22.
6. Bochner BS, Book W, Busse WW et al. Workshop report from the National Institutes of Health Taskforce on the Research Needs of Eosinophil-Associated Diseases (TREAD). J Allergy Clin Immunol 2012; 130:587-96.
7. Gauvreau GM, Denburg JA. Eosinophils and hemopoietic processes in allergic asthma. In: Lee JJ, Rosenberg HF, eds. Eosinophils in health and disease. Amsterdam: Elsevier, 2013:466-76.
8. Haldar P, Pavord ID, Wardlaw AJ. Insights into the pathogenesis of asthma and other eosinophil-mediated diseases from antagonists of interleukin-5 and its receptor. In: Lee JJ, Rosenberg HF, eds. Eosinophils in health and disease. Amsterdam: Elsevier, 2013:579-87.
9. Nair P. Eosinophil-targeted treatment of asthma. In: Lee JJ, Rosenberg HF, eds. Eosinophils in health and disease. Amsterdam: Elsevier, 2013:462-5.
10. Fulkerson PC, Rothenberg ME. Targeting eosinophils in allergy, inflammation and beyond. Nat Rev Drug Discov 2013; 12:117-29.
11. Nadif R, Zerimech F, Bouzigon E, Matran R. The role of eosinophils and basophils in allergic diseases considering genetic findings. Curr Opin Allergy Clin Immunol 2013; 13:507-13.
12. Hogan SP, Rosenberg HF, Moqbel R et al. Eosinophils: biological properties and role in health and disease. Clin Exp Allergy 2008; 38:709-50.
13. Rothenberg ME, Hogan SP. The eosinophil. Annu Rev Immunol 2006; 24:147-74.
14. Pavord ID. Eosinophilic phenotypes of airway disease. Ann Am Thorac Soc 2013; 10(Suppl.):S143-9.
15. Bochner BS, Gleich GJ. What targeting eosinophils has taught us about their role in diseases. J Allergy Clin Immunol 2010; 126:16-25.
16. Wegmann M. Targeting eosinophil biology in asthma therapy. Am J Respir Cell Mol Biol 2011; 45:667-74.
17. Arron JR, Scheerens H, Matthews JG. Redefining approaches to asthma: developing targeted biologic therapies. Adv Pharmacol 2013; 66:1-49.
18. Simpson JL, Scott R, Boyle MJ, Gibson PG. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology 2006; 11:54-61.
19. Haldar P, Pavord ID, Shaw DE et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178:218-24.
20. Woodruff PG, Boushey HA, Dolganov GM et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci USA 2007; 104:15858-63.
21. Hastie AT, Moore WC, Meyers DA et al. Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. J Allergy Clin Immunol 2010; 125(1028-36):e13.
22. Moore WC, Meyers DA, Wenzel SE et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010; 181:315-23.
23. Wang F, He XY, Baines KJ et al. Different inflammatory phenotypes in adults and children with acute asthma. Eur Respir J 2011; 38:567-74.
24. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012; 18:716-25.
25. McGrath KW, Icitovic N, Boushey HA et al. Asthma Clinical Research Network of the National Heart, Lung, and Blood Institute, A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. Am J Respir Crit Care Med 2012; 185:612-9.
26. Pavord ID, Gibson PG. Inflammometry: the current state of play. Thorax 2012; 67:191-2.
27. Moore WC, Hastie AT, Li X et al. Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. J Allergy Clin Immunol 2013, doi:10.1016/j.jaci.2013.10.011 [Epub ahead of print].
28. Lin TY, Poon AH, Hamid Q. Asthma phenotypes and endotypes. Curr Opin Pulm Med 2013; 19:18-23.
29. Simpson JL, McElduff P, Gibson PG. Assessment and reproducibility of non-eosinophilic asthma using induced sputum. Respiration 2010; 79: 147-51.
30. Agache I, Akdis C, Jutel M, Virchow JC. Untangling asthma phenotypes and endotypes. Allergy 2012; 67:835-46.
31. Schleich FN, Manise M, Sele J, Henket M, Seidel L, Louis R. Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammation. BMC Pulm Med 2013; 13:11.
32. Fleming L, Tsartsali L, Wilson N, Regamey N, Bush A. Sputum inflammatory phenotypes are not stable in children with asthma. Thorax 2012; 67:675-81.
33. Haldar P, Brightling CE, Hargadon B et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360:973-84.
34. Nair P, Pizzichini MM, Kjarsgaard M et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009; 360:985-93.
35. Pavord ID, Korn S, Howarth P et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380:651-9.
36. Busse WW, Ring J, Huss-Marp J, Kahn JE. A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma. J Allergy Clin Immunol 2010; 125:803-13.
37. Robinson DS. Mepolizumab treatment for asthma. Expert Opin Biol Ther 2013; 13:295-302.
38. Flood-Page P, Menzies-Gow A, Phipps S et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003; 112:1029-36.
39. Kay AB, Phipps S, Robinson DS. A role for eosinophils in airway remodelling in asthma. Trends Immunol 2004; 25:477-82.
40. Koenderman L. Priming: a critical step in the control of eosinophil activation. In: Lee JJ, Rosenberg HF, eds. Eosinophils in health and disease. Amsterdam: Elsevier, 2013:170-9.
41. Johansson MW, Mosher DF. Integrin activation states and eosinophil recruitment in asthma. Front Pharmacol 2013; 4:33.
42. Barthel SR, Johansson MW, McNamee DM, Mosher DF. Roles of integrin activation in eosinophil function and the eosinophilic inflammation of asthma. J Leukoc Biol 2008; 83:1-12.
43. Rosenberg HF, Phipps S, Foster PS. Eosinophil trafficking in allergy and asthma. J Allergy Clin Immunol 2007; 119:1303-10.
44. Wardlaw AJ. Eosinophil trafficking in asthma. Clin Med 2001; 1:214-8.
45. Hynes RO. Integrins: a family of cell surface receptors. Cell 1987; 48:549-54.
46. Ruoslahti E. Integrins. J Clin Invest 1991; 87:1-5.
47. Evans R, Patzak I, Svensson L et al. Integrins in immunity. J Cell Sci 2009; 122:215-25.
48. Hogg N, Patzak I, Willenbrock F. The insider's guide to leukocyte integrin signalling and function. Nat Rev Immunol 2011; 11:416-26.
49. Humphries JD, Byron A, Humphries MJ. Integrin ligands at a glance. J Cell Sci 2006; 119:3901-3.
50. Margadant C, Monsuur HN, Norman JC, Sonnenberg A. Mechanisms of integrin activation and trafficking. Curr Opin Cell Biol 2011; 23:607-14.
51. Luo BH, Springer TA. Integrin structures and conformational signaling. Curr Opin Cell Biol 2006; 18:579-86.
52. Luo BH, Carman CV, Springer TA. Structural basis of integrin regulation and signaling. Annu Rev Immunol 2007; 25:619-47.
53. Banerjee ER, Jiang Y, Henderson WR Jr, Latchman Y, Papayannopoulou T. Absence of alpha 4 but not beta 2 integrins restrains development of chronic allergic asthma using mouse genetic models. Exp Hematol 2009; 37:715-27.
54. Banerjee ER, Jiang Y, Henderson WR Jr, Scott LM, Papayannopoulou T. Alpha4 and beta2 integrins have nonredundant roles for asthma development, but for optimal allergen sensitization only alpha4 is critical. Exp Hematol 2007; 35:605-17.
55. Tachimoto H, Bochner BS. The surface phenotype of human eosinophils. Chem Immunol 2000; 76:45-62.
56. Ebisawa M, Schleimer RP, Bickel C, Bochner BS. Phenotyping of purified human peripheral blood eosinophils using Blind Panel mAb. In: Schlossman S, Boumsell L, Gilks W, Harlan J, Kishimoto T, Morimoto C, Ritz J, Shaw S, Silverstein R, Springer T, Tedder T, Todd R, eds. Leukocyte Typing V: white cell differentiation antigens. New York: Oxford University Press, 1995:1036-8.
57. Driss V, Legrand F, Capron M. Eosinophil receptor profile. In: Lee JJ, Rosenberg HF, eds. Eosinophils in health and disease. Amsterdam: Elsevier, 2013:30-8.
58. Vijverberg SJ, Koenderman L, Koster ES, van der Ent CK, Raaijmakers JA, Maitland-van der Zee AH. Biomarkers of therapy responsiveness in asthma: pitfalls and promises. Clin Exp Allergy 2011; 41:615-29.
59. Na HJ, Hamilton RG, Klion AD, Bochner BS. Biomarkers of eosinophil involvement in allergic and eosinophilic diseases: review of phenotypic and serum markers including a novel assay to quantify levels of soluble Siglec-8. J Immunol Methods 2012; 383:39-46.
60. Bochner BS. Systemic activation of basophils and eosinophils: markers and consequences. J Allergy Clin Immunol 2000; 106:S292-302.
61. Vijverberg SJ, Hilvering B, Raaijmakers JA, Lammers JW, Maitland-van der Zee AH, Koenderman L. Clinical utility of asthma biomarkers: from bench to bedside. Biologics 2013; 7:199-210.
62. Kita H. Eosinophils: multifunctional and distinctive properties. Int Arch Allergy Immunol 2013; 161(Suppl. 2):3-9.
63. Johansson MW, Kelly EA, Busse WW, Jarjour NN, Mosher DF. Up-regulation and activation of eosinophil integrins in blood and airway after segmental lung antigen challenge. J Immunol 2008; 180:7622-35.
64. Johansson MW, Mosher DF. Activation of beta1 integrins on blood eosinophils by P-selectin. Am J Respir Cell Mol Biol 2011; 45:889-97.
65. Mawhorter SD, Stephany DA, Ottesen EA, Nutman TB. Identification of surface molecules associated with physiologic activation of eosinophils. Application of whole-blood flow cytometry to eosinophils. J Immunol 1996; 156:4851-8.
66. Barthel SR, Jarjour NN, Mosher DF, Johansson MW. Dissection of the hyperadhesive phenotype of airway eosinophils in asthma. Am J Respir Cell Mol Biol 2006; 35:378-86.
67. Johansson MW, Annis DS, Mosher DF. α(M)β(2) integrin-mediated adhesion and motility of IL-5-stimulated eosinophils on periostin. Am J Respir Cell Mol Biol 2013; 48:503-10.
68. Han S-T, Mosher DF. IL-5 induces suspended eosinophils to undergo unique global reorganization associated with priming. Am J Respir Cell Mol Biol 2014; 50:654-64.
69. Rennard SI, Basset G, Lecossier D et al. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol 1986; 60:532-8.
70. Teran LM, Carroll MP, Shute JK, Holgate ST. Interleukin 5 release into asthmatic airways 4 and 24 hours after endobronchial allergen challenge: its relationship with eosinophil recruitment. Cytokine 1999; 11:518-22.
71. Kelly EAB, Busse WW, Jarjour NN. A comparison of the airway response to segmental antigen bronchoprovocation in atopic asthma and allergic rhinitis. J Allergy Clin Immunol 2003; 111:79-86.
72. Woolley KL, Adelroth E, Woolley MJ, Ellis R, Jordana M, O'Byrne PM. Effects of allergen challenge on eosinophils, eosinophil cationic protein, and granulocyte-macrophage colony-stimulating factor in mild asthma. Am J Respir Crit Care Med 1995; 151:1915-24.
73. Evans DJ, Barnes PJ, Spaethe SM, van Alstyne EL, Mitchell MI, O'Connor BJ. Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma. Thorax 1996; 51:1178-84.
74. Jarjour NN, Calhoun WJ, Kelly EA, Gleich GJ, Schwartz LB, Busse WW. The immediate and late allergic response to segmental bronchopulmonary provocation in asthma. Am J Respir Crit Care Med 1997; 155:1515-21.
75. Mastalerz L, Sanak M, Szczeklik A. Serum interleukin-5 in aspirin-induced asthma. Clin Exp Allergy 2001; 31:1036-40.
76. Joseph J, Benedict S, Safa W, Joseph M. Serum interleukin-5 levels are elevated in mild and moderate persistent asthma irrespective of regular inhaled glucocorticoid therapy. BMC Pulm Med 2004; 4:2.
77. Johnsson M, Bove M, Bergquist H et al. Distinctive blood eosinophilic phenotypes and cytokine patterns in eosinophilic esophagitis, inflammatory bowel disease and airway allergy. J Innate Immun 2011; 3:594-604.
78. Pelikan Z. Delayed type of asthmatic response to allergen challenge and cytokines in the peripheral blood. Respiration 2012; 84:385-95.
79. Pelikan Z. Delayed asthmatic response to allergen challenge and cytokines released by nonspecifically stimulated blood cells. ISRN Inflamm 2013; 2013:496208.
80. Patil SP, Wisnivesky JP, Busse PJ, Halm EA, Li XM. Detection of immunological biomarkers correlated with asthma control and quality of life measurements in sera from chronic asthmatic patients. Ann Allergy Asthma Immunol 2011; 106:205-13.
81. Wang TN, Chiang W, Tseng HI et al. The polymorphisms of eotaxin 1 and CCR3 genes influence on serum IgE, eotaxin levels and mild asthmatic children in Taiwan. Allergy 2007; 62:1125-30.
82. Pelikan Z. Chemokine profiles in blood associated with delayed asthmatic response to allergen challenge. Respir Med 2013; 107:47-59.
83. Arima K, Umeshita-Suyama R, Sakata Y et al. Upregulation of IL-13 concentration in vivo by the IL13 variant associated with bronchial asthma. J Allergy Clin Immunol 2002; 109:980-7.
84. Dorman SC, Sehmi R, Gauvreau GM et al. Kinetics of bone marrow eosinophilopoiesis and associated cytokines after allergen inhalation. Am J Respir Crit Care Med 2004; 169:565-72.
85. Sumimoto S, Kawai M, Kasajima Y, Hamamoto T. Increased plasma tumour necrosis factor-alpha concentration in atopic dermatitis. Arch Dis Child 1992; 67:277-9.
86. Lilly CM, Nakamura H, Belostotsky OI et al. Eotaxin expression after segmental allergen challenge in subjects with atopic asthma. Am J Respir Crit Care Med 2001; 163:1669-75.
87. Krisiukeniene A, Babusyte A, Stravinskaite K, Lotvall J, Sakalauskas R, Sitkauskiene B. Smoking affects eotaxin levels in asthma patients. J Asthma 2009; 46:470-6.
88. Min JW, Lee JH, Park CS et al. Association of eotaxin-2 gene polymorphisms with plasma eotaxin-2 concentration. J Hum Genet 2005; 50:118-23.
89. Batra V, Musani AI, Hastie AT et al. Bronchoalveolar lavage fluid concentrations of transforming growth factor (TGF)-beta1, TGF-beta2, interleukin (IL)-4 and IL-13 after segmental allergen challenge and their effects on alpha-smooth muscle actin and collagen III synthesis by primary human lung fibroblasts. Clin Exp Allergy 2004; 34:437-44.
90. Kroegel C, Julius P, Matthys H, Virchow JC Jr, Luttmann W. Endobronchial secretion of interleukin-13 following local allergen challenge in atopic asthma: relationship to interleukin-4 and eosinophil counts. Eur Respir J 1996; 9:899-904.
91. Koenderman L, van der Bruggen T, Schweizer RC et al. Eosinophil priming by cytokines: from cellular signal to in vivo modulation. Eur Respir J Suppl 1996; 22:119s-25s.
92. Coffer PJ, Koenderman L. Granulocyte signal transduction and priming: cause without effect? Immunol Lett 1997; 57:27-31.
93. Hakansson L, Heinrich C, Rak S. Priming of eosinophil adhesion in patients with birch pollen allergy during pollen season: effect of immunotherapy. J Allergy Clin Immunol 1997; 99:551-62.
94. Moser R, Fehr J, Bruijnzeel PLB. IL-4 controls the selective endothelium-driven transmigration of eosinophils from allergic individuals. J Immunol 1992; 149:1432-8.
95. Sehmi R, Wardlaw AJ, Cromwell O, Kurihara K, Waltmann P, Kay AB. Interleukin-5 selectively enhances the chemotactic response of eosinophils obtained from normal but not eosinophilic subjects. Blood 1992; 79:2952-9.
96. Warringa RA, Mengelers HJ, Kuijper PH, Raaijmakers JA, Bruijnzeel PL, Koenderman L. In vivo priming of platelet-activating factor-induced eosinophil chemotaxis in allergic asthmatic individuals. Blood 1992; 79:1836-41.
97. Sannohe S, Adachi T, Hamada K et al. Upregulated response to chemokines in oxidative metabolism of eosinophils in asthma and allergic rhinitis. Eur Respir J 2003; 21:925-31.
98. Moser R, Fehr J, Olgiati L, Bruijnzeel PL. Migration of primed human eosinophils across cytokine-activated endothelial cell monolayers. Blood 1992; 79:2937-45.
99. Warringa RA, Mengelers HJ, Raaijmakers JA, Bruijnzeel PL, Koenderman L. Upregulation of formyl-peptide and interleukin-8-induced eosinophil chemotaxis in patients with allergic asthma. J Allergy Clin Immunol 1993; 91:1198-205.
100. Johansson MW, Gunderson KA, Kelly EA, Denlinger LC, Jarjour NN, Mosher DF. Anti-IL-5 attenuates activation and surface density of beta(2) -integrins on circulating eosinophils after segmental antigen challenge. Clin Exp Allergy 2013; 43:292-303.
101. Hartnell A, Robinson DS, Kay AB, Wardlaw AJ. CD69 is expressed by human eosinophils activated in vivo in asthma and in vitro by cytokines. Immunology 1993; 80:281-6.
102. Nishikawa K, Morii T, Ako H, Hamada K, Saito S, Narita N. In vivo expression of CD69 on lung eosinophils in eosinophilic pneumonia: CD69 as a possible activation marker for eosinophils. J Allergy Clin Immunol 1992; 90:169-74.
103. Matsumoto K, Appiah-Pippim J, Schleimer RP, Bickel CA, Beck LA, Bochner BS. CD44 and CD69 represent different types of cell-surface activation markers for human eosinophils. Am J Respir Cell Mol Biol 1998; 18:860-6.
104. Luttmann W, Matthiesen T, Matthys H, Virchow JC Jr. Synergistic effects of interleukin-4 or interleukin-13 and tumor necrosis factor-alpha on eosinophil activation in vitro. Am J Respir Cell Mol Biol 1999; 20:474-80.
105. Julius P, Luttmann W, Knoechel B, Kroegel C, Matthys H, Virchow JC Jr. CD69 surface expression on human lung eosinophils after segmental allergen provocation. Eur Respir J 1999; 13:1253-9.
106. Dallaire MJ, Ferland C, Lavigne S, Chakir J, Laviolette M. Migration through basement membrane modulates eosinophil expression of CD44. Clin Exp Allergy 2002; 32:898-905.
107. Liu LY, Sedgwick JB, Bates ME et al. Decreased expression of membrane IL-5 receptor alpha on human eosinophils: II. IL-5 down-modulates its receptor via a proteinase-mediated process. J Immunol 2002; 169:6459-66.
108. Gregory B, Kirchem A, Phipps S et al. Differential regulation of human eosinophil IL-3, IL-5, and GM-CSF receptor alpha-chain expression by cytokines: IL-3, IL-5, and GM-CSF down-regulate IL-5 receptor alpha expression with loss of IL-5 responsiveness, but up-regulate IL-3 receptor alpha expression. J Immunol 2003; 170:5359-66.
109. Kelly EA, Koziol-White CJ, Clay KJ et al. Potential contribution of IL-7 to allergen-induced eosinophilic airway inflammation in asthma. J Immunol 2009; 182:1404-10.
110. Bates ME, Liu LY, Esnault S et al. Expression of interleukin-5- and granulocyte macrophage-colony-stimulating factor-responsive genes in blood and airway eosinophils. Am J Respir Cell Mol Biol 2004; 30:736-43.
111. Pignatti P, Perfetti L, Galdi E et al. Increased CD69 expression on peripheral blood eosinophils after specific inhalation challenge. Allergy 2002; 57:411-6.
112. Kanters D, ten Hove W, Luijk B et al. Expression of activated Fc gamma RII discriminates between multiple granulocyte-priming phenotypes in peripheral blood of allergic asthmatic subjects. J Allergy Clin Immunol 2007; 120:1073-81.
113. Neeley SP, Hamann KJ, White SR, Baranowski SL, Burch RA, Leff AR. Selective regulation of expression of surface adhesion molecules Mac-1, L-selectin, and VLA-4 on human eosinophils and neutrophils. Am J Respir Cell Mol Biol 1993; 8:633-9.
114. Wong CK, Hu S, Cheung PF, Lam CW. Thymic stromal lymphopoietin induces chemotactic and prosurvival effects in eosinophils: implications in allergic inflammation. Am J Respir Cell Mol Biol 2010; 43:305-15.
115. Bennett TA, Lynam EB, Sklar LA, Rogelj S. Hydroxamate-based metalloprotease inhibitor blocks shedding of L-selectin adhesion molecule from leukocytes: functional consequences for neutrophil aggregation. J Immunol 1996; 156:3093-7.
116. Mengelers HJ, Maikoe T, Hooibrink B et al. Down modulation of L-selectin expression on eosinophils recovered from bronchoalveolar lavage fluid after allergen provocation. Clin Exp Allergy 1993; 23:196-204.
117. Georas SN, Liu MC, Newman W, Dawson Beall L, Stealey BA, Bochner BS. Altered adhesion molecule expression and endothelial cell activation accompany the recruitment of human granulocytes to the lung after segmental antigen challenge. Am J Respir Cell Mol Biol 1992; 7:261-9.
118. Mengelers HJ, Maikoe T, Brinkman L, Hooibrink B, Lammers JW, Koenderman L. Immunophenotyping of eosinophils recovered from blood and BAL of allergic asthmatics. Am J Respir Crit Care Med 1994; 149:345-51.
119. in't Veen JC, Grootendorst DC, Bel EH et al. CD11b and L-selectin expression on eosinophils and neutrophils in blood and induced sputum of patients with asthma compared with normal subjects. Clin Exp Allergy 1998; 28:606-15.
120. Hansel TT, Braunstein JB, Walker C et al. Sputum eosinophils from asthmatics express ICAM-1 and HLA-DR. Clin Exp Immunol 1991; 86:271-7.
121. Czech W, Krutmann J, Budnik A, Schopf E, Kapp A. Induction of intercellular adhesion molecule 1 (ICAM-1) expression in normal human eosinophils by inflammatory cytokines. J Invest Dermatol 1993; 100:417-23.
122. Hansel TT, De Vries IJ, Carballido JM et al. Induction and function of eosinophil intercellular adhesion molecule-1 and HLA-DR. J Immunol 1992; 149:2130-6.
123. Wong CK, Ip WK, Lam CW. Interleukin-3, -5, and granulocyte macrophage colony-stimulating factor-induced adhesion molecule expression on eosinophils by p38 mitogen-activated protein kinase and nuclear factor-[kappa] B. Am J Respir Cell Mol Biol 2003; 29:133-47.
124. Sano K, Yamauchi K, Hoshi H, Honma M, Tamura G, Shirato K. CD44 expression on blood eosinophils is a novel marker of bronchial asthma. Int Arch Allergy Immunol 1997; 114(Suppl 1):67-71.
125. Sakamoto S, Oki K, Takahashi H et al. Comparison of surface antigens on eosinophils from patients with eosinophilia. Int Arch Allergy Immunol 1996; 111(Suppl. 1):26-8.
126. Katoh S, Matsumoto N, Kawakita K, Tominaga A, Kincade PW, Matsukura S. A role for CD44 in an antigen-induced murine model of pulmonary eosinophilia. J Clin Invest 2003; 111:1563-70.
127. Rothenberg ME. CD44-a sticky target for asthma. J Clin Invest 2003; 111:1460-2.
128. Matsumoto K, Bochner BS. Adhesion molecules. In: Lee JJ, Rosenberg HF, eds. Eosinophils in health and disease. Amsterdam: Elsevier, 2013:131-9.
129. Symon FA, Lawrence MB, Williamson ML, Walsh GM, Watson SR, Wardlaw AJ. Functional and structural characterization of the eosinophil P-selectin ligand. J Immunol 1996; 157:1711-9.
130. Johansson MW, Han ST, Gunderson KA, Busse WW, Jarjour NN, Mosher DF. Platelet activation, P-selectin, and eosinophil beta1-integrin activation in asthma. Am J Respir Crit Care Med 2012; 185:498-507.
131. Davenpeck KL, Brummet ME, Hudson SA, Mayer RJ, Bochner BS. Activation of human leukocytes reduces surface P-selectin glycoprotein ligand-1 (PSGL-1, CD162) and adhesion to P-selectin in vitro. J Immunol 2000; 165:2764-72.
132. Gauvreau GM, Evans MY. Allergen inhalation challenge: a human model of asthma exacerbation. Contrib Microbiol 2007; 14:21-32.
133. Diamant Z, Gauvreau GM, Cockcroft DW et al. Inhaled allergen bronchoprovocation tests. J Allergy Clin Immunol 2013; 132(1045-55):e6.
134. Rand TH, Silberstein DS, Kornfeld H, Weller PF. Human eosinophils express functional interleukin 2 receptors. J Clin Invest 1991; 88:825-32.
135. Riedel D, Lindemann A, Brach M, Mertelsmann R, Herrmann F. Granulocyte-macrophage colony-stimulating factor and interleukin-3 induce surface expression of interleukin-2 receptor p55-chain and CD4 by human eosinophils. Immunology 1990; 70:258-61.
136. Esnault S, Kelly EA, Johansson MW et al. Semaphorin 7A is expressed on airway eosinophils and upregulated by IL-5 family cytokines. Clin Immunol 2013; 150:90-100.
137. Liu LY, Sedgwick JB, Bates ME et al. Decreased expression of membrane IL-5 receptor alpha on human eosinophils: I. Loss of membrane IL-5 receptor alpha on airway eosinophils and increased soluble IL-5 receptor alpha in the airway after allergen challenge. J Immunol 2002; 169:6452-8.
138. Stein ML, Villanueva JM, Buckmeier BK et al. Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. J Allergy Clin Immunol 2008; 121:1473-83.
139. Myrtek D, Knoll M, Matthiesen T et al. Expression of interleukin-13 receptor alpha 1-subunit on peripheral blood eosinophils is regulated by cytokines. Immunology 2004; 112:597-604.
140. Tang W, Smith SG, Beaudin S et al. IL-25 and IL-25 receptor expression on eosinophils from subjects with allergic asthma. Int Arch Allergy Immunol 2013; 163:5-10.
141. Monteiro RC, Hostoffer RW, Cooper MD, Bonner JR, Gartland GL, Kubagawa H. Definition of immunoglobulin A receptors on eosinophils and their enhanced expression in allergic individuals. J Clin Invest 1993; 92:1681-5.
142. Hartnell A, Kay AB, Wardlaw AJ. IFN-gamma induces expression of Fc gamma RIII (CD16) on human eosinophils. J Immunol 1992; 148:1471-8.
143. Valerius T, Repp R, Kalden JR, Platzer E. Effects of IFN on human eosinophils in comparison with other cytokines. A novel class of eosinophil activators with delayed onset of action. J Immunol 1990; 145:2950-8.
144. Zhu X, Hamann KJ, Munoz NM et al. Intracellular expression of Fc gamma RIII (CD16) and its mobilization by chemoattractants in human eosinophils. J Immunol 1998; 161:2574-9.
145. Davoine F, Lavigne S, Chakir J, Ferland C, Boulay ME, Laviolette M. Expression of FcgammaRIII (CD16) on human peripheral blood eosinophils increases in allergic conditions. J Allergy Clin Immunol 2002; 109:463-9.
146. Luijk B, Lindemans CA, Kanters D et al. Gradual increase in priming of human eosinophils during extravasation from peripheral blood to the airways in response to allergen challenge. J Allergy Clin Immunol 2005; 115:997-1003.
147. Kishimoto T, Kikutani H, von dem Borne AEG et al. Leucocyte typing VI: white cell differentiation antigens. New York: Garland Publishing Inc, 1997.
148. Wardlaw AJ, Jeffrey PK, Majumdar S et al. Platelet adhesion to eosinophils. Am Rev Respir Dis 1992; 145:A664.
149. Laidlaw TM, Boyce JA. Cysteinyl leukotriene receptors, old and new; implications for asthma. Clin Exp Allergy 2012; 42:1313-20.
150. Pitchford SC, Momi S, Giannini S et al. Platelet P-selectin is required for pulmonary eosinophil and lymphocyte recruitment in a murine model of allergic inflammation. Blood 2005; 105:2074-81.
151. Pitchford SC, Yano H, Lever R et al. Platelets are essential for leukocyte recruitment in allergic inflammation. J Allergy Clin Immunol 2003; 112:109-18.
152. Page C, Pitchford S. Platelets coming of age: implications for our understanding of allergic inflammation. Am J Respir Crit Care Med 2013; 187:459-60.
153. de Bruijne-Admiraal LG, Modderman PW, Von dem Borne AE, Sonnenberg A. P-selectin mediates Ca(2+)-dependent adhesion of activated platelets to many different types of leukocytes: detection by flow cytometry. Blood 1992; 80:134-42.
154. Bazan-Socha S, Bukiej A, Pulka G, Marcinkiewicz C, Musial J. Increased expression of collagen receptors: alpha1beta1 and alpha2beta1 integrins on blood eosinophils in bronchial asthma. Clin Exp Allergy 2006; 36:1184-91.
155. Bazan-Socha S, Zuk J, Plutecka H, Marcinkiewicz C, Zareba L, Musial J. Collagen receptors alpha(1)beta(1) and alpha(2)beta(1) integrins are involved in transmigration of peripheral blood eosinophils, but not mononuclear cells through human microvascular endothelial cells monolayer. J Physiol Pharmacol 2012; 63:373-9.
156. Kuijpers TW, Mul EPJ, Blom M et al. Freezing adhesion molecules in a state of high-avidity binding blocks eosinophil migration. J Exp Med 1993; 178:279-84.
157. Chin JE, Hatfield CA, Winterrowd GE et al. Airway recruitment of leukocytes in mice is dependent on alpha4-integrins and vascular cell adhesion molecule-1. Am J Physiol 1997; 272:L219-29.
158. Cook-Mills JM. Eosinophil-endothelial cell interactions during inflammation. In: Lee JJ, Rosenberg HF, eds. Eosinophils in health and disease. Amsterdam: Elsevier, 2013:139-53.
159. Barthel SR, Annis DS, Mosher DF, Johansson MW. Differential engagement of modules 1 and 4 of vascular cell adhesion molecule-1 (CD106) by integrins alpha4beta1 (CD49d/29) and alphaMbeta2 (CD11b/18) of eosinophils. J Biol Chem 2006; 281:32175-87.
160. Zhu X, Munoz NM, Kim KP, Sano H, Cho W, Leff AR. Cytosolic phospholipase A2 activation is essential for beta 1 and beta 2 integrin-dependent adhesion of human eosinophils. J Immunol 1999; 163:3423-9.
161. Lantero S, Alessandri G, Spallarossa D, Scarso L, Rossi GA. LFA-1 expression by blood eosinophils is increased in atopic asthmatic children and is involved in eosinophil locomotion. Eur Respir J 1998; 12:1094-8.
162. Tenscher K, Metzner B, Schopf E, Norgauer J, Czech W. Recombinant human eotaxin induces oxygen radical production, Ca(2 + )-mobilization, actin reorganization, and CD11b upregulation in human eosinophils via a pertussis toxin-sensitive heterotrimeric guanine nucleotide-binding protein. Blood 1996; 88:3195-9.
163. Liu L, Hakansson L, Ridefelt P, Garcia RC, Venge P. Priming of eosinophil migration across lung epithelial cell monolayers and upregulation of CD11b/CD18 are elicited by extracellular Ca2+. Am J Respir Cell Mol Biol 2003; 28:713-21.
164. Kroegel C, Liu MC, Hubbard WC, Lichtenstein LM, Bochner BS. Blood and bronchoalveolar eosinophils in allergic subjects after segmental antigen challenge: surface phenotype, density heterogeneity, and prostanoid production. J Allergy Clin Immunol 1994; 93:725-34.
165. Dichmann S, Idzko M, Zimpfer U et al. Adenosine triphosphate-induced oxygen radical production and CD11b up-regulation: Ca(++) mobilization and actin reorganization in human eosinophils. Blood 2000; 95:973-8.
166. Suzukawa M, Koketsu R, Iikura M et al. Interleukin-33 enhances adhesion, CD11b expression and survival in human eosinophils. Lab Invest 2008; 88:1245-53.
167. Walsh GM, Hartnell A, Wardlaw AJ, Kurihara K, Sanderson CJ, Kay AB. IL-5 enhances the in vitro adhesion of human eosinophils, but not neutrophils, in a leucocyte integrin (CD11/18)-dependent manner. Immunology 1990; 71:258-65.
168. Thorne KJ, Richardson BA, Mazza G, Butterworth AE. A new method for measuring eosinophil activating factors, based on the increased expression of CR3 alpha chain (CD11b) on the surface of activated eosinophils. J Immunol Methods 1990; 133:47-54.
169. Lundahl J, Hallden G, Hed J. Differences in intracellular pool and receptor-dependent mobilization of the adhesion-promoting glycoprotein Mac-1 between eosinophils and neutrophils. J Leukoc Biol 1993; 53:336-41.
170. Fernvik E, Gronneberg R, Lundahl J et al. The degree of natural allergen exposure modifies eosinophil activity markers in the circulation of patients with mild asthma. Allergy 1996; 51:697-705.
171. Sedgwick JB, Calhoun WJ, Vrtis RF, Bates ME, McAllister PK, Busse WW. Comparison of airway and blood eosinophil function after in vivo antigen challenge. J Immunol 1992; 149:3710-8.
172. Grayson MH, Van der Vieren M, Sterbinsky SA et al. AlphaDbeta2 Integrin is expressed on human eosinophils and functions as an alternative ligand for vascular cell adhesion molecule 1 (VCAM-1). J Exp Med 1998; 188:2187-91.
173. Huttenlocher A, Ginsberg MH, Horwitz AF. Modulation of cell migration by integrin-mediated cytoskeletal linkages and ligand-binding affinity. J Cell Biol 1996; 134:1551-62.
174. Palecek SP, Loftus JC, Ginsberg MH, Lauffenburger DA, Horwitz AF. Integrin-ligand binding properties govern cell migration speed through cell-substratum adhesiveness. Nature 1997; 385:537-40.
175. Askari JA, Buckley PA, Mould AP, Humphries MJ. Linking integrin conformation to function. J Cell Sci 2009; 122:165-70.
176. Humphries MJ. Monoclonal antibodies as probes of integrin priming and activation. Biochem Soc Trans 2004; 32:407-11.
177. Byron A, Humphries JD, Askari JA, Craig SE, Mould AP, Humphries MJ. Anti-integrin monoclonal antibodies. J Cell Sci 2009; 122:4009-11.
178. Harburger DS, Calderwood DA. Integrin signalling at a glance. J Cell Sci 2009; 122:159-63.
179. Shattil SJ, Kim C, Ginsberg MH. The final steps of integrin activation: the end game. Nat Rev Mol Cell Biol 2010; 11:288-300.
180. Johansson MW, Barthel SR, Swenson CA et al. Eosinophil beta 1 integrin activation state correlates with asthma activity in a blind study of inhaled corticosteroid withdrawal. J Allergy Clin Immunol 2006; 117:1502-4.
181. Wilkins JA, Li A, Ni H, Stupack DG, Shen C. Control of beta1 integrin function. Localization of stimulatory epitopes. J Biol Chem 1996; 271:3046-51.
182. Ni H, Li A, Simonsen N, Wilkins JA. Integrin activation by dithiothreitol or Mn2+ induces a ligand-occupied conformation and exposure of a novel NH2-terminal regulatory site on the beta1 integrin chain. J Biol Chem 1998; 273:7981-7.
183. Coe AP, Askari JA, Kline AD et al. Generation of a minimal alpha5beta1 integrin-Fc fragment. J Biol Chem 2001; 276:35854-66.
184. Mould AP, Travis MA, Barton SJ et al. Evidence that monoclonal antibodies directed against the integrin beta subunit plexin/semaphorin/integrin domain stimulate function by inducing receptor extension. J Biol Chem 2005; 280:4238-46.
185. Lenter M, Uhlig H, Hamann A, Jeno P, Imhof B, Vestweber D. A monoclonal antibody against an activation epitope on mouse integrin chain beta 1 blocks adhesion of lymphocytes to the endothelial integrin alpha 6 beta 1. Proc Natl Acad Sci USA 1993; 90:9051-5.
186. Bazzoni G, Shih DT, Buck CA, Hemler ME. Monoclonal antibody 9EG7 defines a novel beta 1 integrin epitope induced by soluble ligand and manganese, but inhibited by calcium. J Biol Chem 1995; 270:25570-7.
187. Luque A, Gomez M, Puzon W, Takada Y, Sanchez-Madrid F, Cabanas C. Activated conformations of very late activation integrins detected by a group of antibodies (HUTS) specific for a novel regulatory region (355-425) of the common beta 1 chain. J Biol Chem 1996; 271:11067-75.
188. Johansson MW, Kruger SJ, Schiebler ML et al. Markers of vascular perturbation correlate with airway structural change in asthma. Am J Respir Crit Care Med 2013; 188:167-78.
189. Ulfman LH, Joosten DP, van Aalst CW et al. Platelets promote eosinophil adhesion of patients with asthma to endothelium under flow conditions. Am J Respir Cell Mol Biol 2003; 28:512-9.
190. Ramos-Barbon D, Fraga-Iriso R, Brienza NS et al. T Cells localize with proliferating smooth muscle alpha-actin+ cell compartments in asthma. Am J Respir Crit Care Med 2010; 182:317-24.
191. Robinson MK, Andrew D, Rosen H et al. Antibody against the Leu-CAM beta-chain (CD18) promotes both LFA-1- and CR3-dependent adhesion events. J Immunol 1992; 148:1080-5.
192. Beglova N, Blacklow SC, Takagi J, Springer TA. Cysteine-rich module structure reveals a fulcrum for integrin rearrangement upon activation. Nat Struct Biol 2002; 9:282-7.
193. Dransfield I, Hogg N. Regulated expression of Mg2+ binding epitope on leukocyte integrin alpha subunits. EMBO J 1989; 8:3759-65.
194. Leitinger B, Hogg N. Effects of I domain deletion on the function of the beta2 integrin lymphocyte function-associated antigen-1. Mol Biol Cell 2000; 11:677-90.
195. Lu C, Shimaoka M, Zang Q, Takagi J, Springer TA. Locking in alternate conformations of the integrin alphaLbeta2 I domain with disulfide bonds reveals functional relationships among integrin domains. Proc Natl Acad Sci USA 2001; 98:2393-8.
196. Oxvig C, Lu C, Springer TA. Conformational changes in tertiary structure near the ligand binding site of an integrin I domain. Proc Natl Acad Sci USA 1999; 96:2215-20.
197. Weber C, Kitayama J, Springer TA. Differential regulation of beta 1 and beta 2 integrin avidity by chemoattractants in eosinophils. Proc Natl Acad Sci USA 1996; 93:10939-44.
198. Ulfman LH, Alblas J, van Aalst CW, Zwaginga JJ, Koenderman L. Differences in potency of CXC chemokine ligand 8-, CC chemokine ligand 11-, and C5a-induced modulation of integrin function on human eosinophils. J Immunol 2005; 175:6092-9.
199. Munitz A, Bachelet I, Eliashar R et al. CD48 is an allergen and IL-3-induced activation molecule on eosinophils. J Immunol 2006; 177:77-83.
200. Rao SP, Wang Z, Zuberi RI et al. Galectin-3 functions as an adhesion molecule to support eosinophil rolling and adhesion under conditions of flow. J Immunol 2007; 179:7800-7.
201. Ge XN, Bahaie NS, Kang BN et al. Allergen-induced airway remodeling is impaired in galectin-3-deficient mice. J Immunol 2010; 185:1205-14.
202. Zuberi RI, Hsu DK, Kalayci O et al. Critical role for galectin-3 in airway inflammation and bronchial hyperresponsiveness in a murine model of asthma. Am J Pathol 2004; 165: 2045-53.
203. Ilmarinen P, James A, Moilanen E et al. Enhanced expression of neuropeptide S (NPS) receptor in eosinophils from severe asthmatics and subjects with total IgE above 100 IU/ml. Peptides 2014; 51:100-9.
204. Calafat J, Kuijpers TW, Janssen H, Borregaard N, Verhoeven AJ, Roos D. Evidence for small intracellular vesicles in human blood phagocytes containing cytochrome b558 and the adhesion molecule CD11b/CD18. Blood 1993; 81:3122-9.
205. Jarjour NN, Erzurum SC, Bleecker ER et al. Severe asthma: lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program. Am J Respir Crit Care Med 2012; 185:356-62.
206. Moore WC, Fitzpatrick AM, Li X et al. Clinical heterogeneity in the Severe Asthma Research Program. Ann Am Thorac Soc 2013; 10(Suppl.):S118-24.
207. Johansson MW, Han S-T, Gunderson KA et al. Platelet activation, P-selectin mobilization, and eosinophil beta1 integrin activation occur in asthma and are associated with clinical phenotypes [abstract]. Am J Respir Crit Care Med 2011; 183:A4335.
208. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76:301-14.
209. Alon R, Dustin ML. Force as a facilitator of integrin conformational changes during leukocyte arrest on blood vessels and antigen-presenting cells. Immunity 2007; 26:17-27.
210. Berends C, Hoekstra MO, Dijkhuizen B, DeMonchy JGR, Gerritsen J, Kauffman HF. Expression of CD35 (CR1) and CD11b (CR3) on circulating neutrophils and eosinophils from allergic asthmatic children. Clin Exp Allergy 1993; 23:926-33.
211. Mahmudi-Azer S, Downey GP, Moqbel R. Translocation of the tetraspanin CD63 in association with human eosinophil mediator release. Blood 2002; 99:4039-47.
212. Braun RK, Foerster M, Workalemahu G, Haefner D, Kroegel C, Walker C. Differential regulation of aminopeptidase N (CD13) by transendothelial migration and cytokines on human eosinophils. Exp Lung Res 2003; 29:59-77.
213. Weller PF, Rand TH, Barrett T, Elovic A, Wong DT, Finberg RW. Accessory cell function of human eosinophils. HLA-DR-dependent, MHC-restricted antigen-presentation and IL-1 alpha expression. J Immunol 1993; 150: 2554-62.
214. Cook EB, Stahl JL, Schwantes EA, Fox KE, Mathur SK. IL-3 and TNFalpha increase Thymic Stromal Lymphopoietin Receptor (TSLPR) expression on eosinophils and enhance TSLP-stimulated degranulation. Clin Mol Allergy 2012; 10:8.